Disc Medicine IRON 深 沪
等待开盘 10-29 09:30:00 美东时间
83.20
+3.300
+4.13%
华盛通- 最 高83.635
- 今 开78.88
- 成交量 110.05万股
- 最 低 78.88
- 昨 收 79.90
- 总市值 36.93亿
- 52周最高 99.50
- 市盈率 静 --
- 换手率 2.48%
- 52周最低 40.0001
- 委 比 4.85%
- 总股本 4439.28万
- 历史最高 190.85
- 量 比 0.51
- 振 幅 5.95%
- 历史最低 11.60
- 每 手 1
- 风险率 9.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股前瞻 | SpaceX、奈飞盘后将公布财报！存储再遭抛售，SK海力士跌近5%，高盛指对冲基金正减持科技股！
SpaceX、奈飞盘后将公布财报！存储再遭抛售，SK海力士跌近5%，高盛指对冲基金正减持科技股；布伦特原油升破110美元关口！创近五月来新高>>
10-20 20:22
美股牛股 | 生物医药股集体大涨，SLN 暴升125.6%，获默克收购；IRON 劲升38.9%，三期临床试验取得积极结果；CLF 业绩扭亏升16.3%
生物医药股集体大涨，SLN 暴升125.6%，获默克收购；IRON 劲升38.9%，三期临床试验取得积极结果；CLF 业绩扭亏升16.3%
10-20 14:37
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine, Inc. will host a webcast on October 19, 2026, at 8:00 a.m. ET to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP). Bitopertin, an investigational GlyT1 inhibitor, aims to modulate heme biosynthesis and is being developed as a potential first disease-modifying therapy for hematologic diseases like EPP. The company has conducted multiple clinical trials, including the Phase 3 ...
10-18 21:00
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
Disc Medicine Inc. (NASDAQ:IRON) on Wednesday shared initial results from the company’s RESTORE-PV Phase 2 update. Initial RESTORE-PV Phase 2 Results Disc said initial RESTORE-PV data showed its investigational DISC-3405 increased hepcidin and lowered serum iron, which the company linked to controll...
09-10 23:08
Disc Medicine reports promising DISC-3405 Phase 2 data
Disc Medicine ( ($IRON) ) has shared an update. On September 9, 2026, Disc Medi...
09-10 21:19
Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.
09-10 21:07
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
Disc Medicine presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV) patients. The data showed that DISC-3405 increased hepcidin, lowered serum iron, controlled hematocrit, reduced phlebotomy events, and improved symptoms. DISC-3405 is the first monoclonal antibody targeting TMPRSS6 to demonstrate phlebotomy reduction in PV. The company also highlighted positive results from the Phase 2 RALLY-M...
09-09 23:25
